Hypoxia-inducible factor 1 and cancer pathogenesis
✍ Scribed by Gregg L. Semenza
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 235 KB
- Volume
- 60
- Category
- Article
- ISSN
- 1521-6543
- DOI
- 10.1002/iub.93
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Hypoxia‐inducible factor 1 (HIF‐1) is a transcriptional activator that mediates adaptive responses to hypoxia. HIF‐1 activity is increased in the majority of human cancers as a result of genetic alterations and intratumoral hypoxia. HIF‐1 activates the transcription of genes that increase O~2~ availability by stimulating angiogenesis or that reprogram cellular metabolism to adapt to reduced O~2~ availability. Proof of principle studies in mouse models suggests that inhibition of HIF‐1 activity may have therapeutic effects, especially in combination with other anticancer drugs. © 2008 IUBMB IUBMB Life, 60(9): 591–597, 2008
📜 SIMILAR VOLUMES
## Abstract Alternative strategies are needed to control growth of advanced and hormone refractory prostate cancer. In this regard, we investigated the efficacy of methylseleninic acid (MSeA), a penultimate precursor to the highly reactive selenium metabolite, methylselenol, to inhibit growth of in
## Abstract With an incidence of about 300 000 new cases colorectal cancer (CRC) is the second leading cause of cancer‐related death in Europe and the United States. Environmental and genetic factors influence CRC risk. Hypoxia‐inducible factor‐1 (HIF‐1), a heterodimeric protein composed of two sub